Alternative approaches for the treatment of airway diseases: focus on nanoparticle medicine

Clinical and Experimental Allergy

Volumn 46, Issue 8, 2016, Pages 1033-1042

  Ratemi, E ^a   Sultana Shaik, A ^b,c   Al Faraj, A ^d   Halwani, R ^b  

^a JUBAIL INDUSTRIAL COLLEGE   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; CARBON NANOTUBE; DENDRIMER; GOLD NANOPARTICLE; LIPOSOME; NANOCARRIER; NANOPARTICLE; QUANTUM DOT;

ASTHMA; BIOSAFETY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE CONTROL; DRUG DELIVERY SYSTEM; GENE DELIVERY SYSTEM; HUMAN; IMAGING; INFLAMMATORY DISEASE; NANOMEDICINE; NANOTECHNOLOGY; PRIORITY JOURNAL; REVIEW; SEVERE PERSISTENT ASTHMA;

EID: 84979642483     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12771     Document Type: Review

References (92)

1. Pakhale S, Mulpuru S, Boyd M. Optimal management of severe/refractory asthma. Clin Med Insights Circ Respir Pulm Med 2011; 5:37–47.
2. Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol 2003; 178:347–55.
3. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19:61–7.
4. Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immun 2012; 129:1229–35.
5. Trevor JL, Deshane JS. Refractory asthma: mechanisms, targets, and therapy. Allergy 2014; 69:817–27.
6. Castro M, Wenzel SE, Bleecker ER et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2:879–90.
7. Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062–71.
8. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973–84.
9. Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985–93.
10. Nowak RM, Parker JM, Silverman RA et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma. Am J Emerg Med 2015; 33:14–20.
11. Martin RJ, Szefler SJ, Chinchilli VM et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002; 165:1377–83.
12. Randell TL, Donaghue KC, Ambler GR, Cowell CT, Fitzgerald DA, van Asperen PP. Safety of the newer inhaled corticosteroids in childhood asthma. Paediatr Drugs 2003; 5:481–504.
13. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7:771–82.
14. Chen G, Roy I, Yang C, Prasad PN. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy. Chem Rev 2016; 116:2826–85.
15. Ding Y, Jiang Z, Saha K et al. Gold nanoparticles for nucleic acid delivery. Mol Ther 2014; 22:1075–83.
16. Draz MS, Fang BA, Zhang P et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 2014; 4:872–92.
17. Elsabahy M, Heo GS, Lim SM, Sun G, Wooley KL. Polymeric nanostructures for imaging and therapy. Chem Rev 2015; 115:10967–1011.
18. Kirkpatrick DL, Weiss M, Naumov A, Bartholomeusz G, Weisman RB, Gliko O. Carbon nanotubes: solution for the therapeutic delivery of siRNA? Materials 2012; 5:278–301.
19. Madaan K, Kumar S, Poonia N, Lather V, Pandita D. Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci 2014; 6:139–50.
20. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology. 2011; 9:55.
21. Rosenthal SJ, Chang JC, Kovtun O, McBride JR, Tomlinson ID. Biocompatible quantum dots for biological applications. Chem Biol 2011; 18:10–24.
22. Thulasiramaraju TV, Babu AMSS, Arunachalam A, Prathap M, Srikanth S, Sivaiah P. Liposomes: a novel drug delivery system. Int J Biopharm 2012; 3:12.
23. Yavuz B, Pehlivan SB, Vural I, Unlu N. In vitro/in vivo evaluation of dexamethasone–PAMAM dendrimer complexes for retinal drug delivery. J Pharm Sci 2015; 104:3814–23.
24. Balazs DA, Godbey W. Liposomes for use in gene delivery. J Drug Deliv 2011; 2011:326497.
25. Kim HJ, Miyata K, Nomoto T et al. siRNA delivery from triblock copolymer micelles with spatially-ordered compartments of PEG shell, siRNA-loaded intermediate layer, and hydrophobic core. Biomaterials 2014; 35:4548–56.
26. Schmitt F, Juillerat-Jeanneret L. Drug targeting strategies for photodynamic therapy. Anticancer Agents Med Chem 2012; 12:500–25.
27. Bergey EJ, Levy L, Wang XP et al. DC magnetic field induced magnetocytolysis of cancer cells targeted by LH-RH magnetic nanoparticles in vitro. Biomed Microdevices 2002; 4:293–9.
28. Al Faraj A, Shaik AP, Shaik AS. Magnetic single-walled carbon nanotubes as efficient drug delivery nanocarriers in breast cancer murine model: noninvasive monitoring using diffusion-weighted magnetic resonance imaging as sensitive imaging biomarker. Int J Nanomedicine 2015; 10:157–68.
29. Al Faraj A, Shaik AP, Shaik AS. Effect of surface coating on the biocompatibility and in vivo MRI detection of iron oxide nanoparticles after intrapulmonary administration. Nanotoxicology 2015; 9:825–34.
30. Al Faraj A, Shaik AS, Afzal S, Al-Muhsen S, Halwani R. Specific targeting and noninvasive magnetic resonance imaging of an asthma biomarker in the lung using polyethylene glycol functionalized magnetic nanocarriers. Contrast Media Mol Imaging 2015; 11:172–83.
31. Al Faraj A, Shaik AS, Al Sayed B. Preferential magnetic targeting of carbon nanotubes to cancer sites: noninvasive tracking using MRI in a murine breast cancer model. Nanomedicine (Lond) 2015; 10:931–48.
32. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997; 54(Suppl. 4):15–21.
33. Moreno-Aspitia A, Perez EA. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Future Oncol 2005; 1:755–62.
34. Zeidan A, Wang ES, Wetzler M. Pegasparaginase: where do we stand? Expert Opin Biol Ther 2009; 9:111–9.
35. Mason RJB, Broaddus VC, Martin TR et al. In: Nedal's EM, ed. Textbook of respiratory medicine. Philadelphia: Saunders Elsevier, 2010: 2400.
36. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006; 2:711–9.
37. Fujita Y, Takeshita F, Kuwano K, Ochiya T. RNAi therapeutic platforms for lung diseases. Pharmaceuticals (Basel) 2013; 6:223–50.
38. Kumar M, Kong X, Behera AK, Hellermann GR, Lockey RF, Mohapatra SS. Chitosan IFN-gamma-pDNA nanoparticle (CIN) therapy for allergic asthma. Genet Vaccines Ther 2003; 1:3.
39. Kong X, Hellermann GR, Zhang W et al. Chitosan interferon-gamma nanogene therapy for lung disease: modulation of T-cell and dendritic cell immune responses. Allergy Asthma Clin Immunol 2008; 4:95–105.
40. Conti DS, Brewer D, Grashik J, Avasarala S, da Rocha SR. Poly(amidoamine) dendrimer nanocarriers and their aerosol formulations for siRNA delivery to the lung epithelium. Mol Pharm 2014; 11:1808–22.
41. Khan OF, Zaia EW, Jhunjhunwala S et al. Dendrimer-inspired nanomaterials for the in vivo delivery of siRNA to lung vasculature. Nano Lett 2015; 15:3008–16.
42. Lee DW, Shirley SA, Lockey RF, Mohapatra SS. Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline. Respir Res 2006; 7:112.
43. Oyarzun-Ampuero FA, Brea J, Loza MI, Torres D, Alonso MJ. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. Int J Pharm 2009; 381:122–9.
44. Oyarzun-Ampuero FA, Brea J, Loza MI, Alonso MJ, Torres D. A potential nanomedicine consisting of heparin-loaded polysaccharide nanocarriers for the treatment of asthma. Macromol Biosci 2012; 12:176–83.
45. Matsuo Y, Ishihara T, Ishizaki J, Miyamoto K, Higaki M, Yamashita N. Effect of betamethasone phosphate loaded polymeric nanoparticles on a murine asthma model. Cell Immunol 2009; 260:33–8.
46. Kenyon NJ, Bratt JM, Lee J et al. Self-assembling nanoparticles containing dexamethasone as a novel therapy in allergic airways inflammation. PLoS One 2013; 8:e77730.
47. Kim H, Park HT, Tae YM et al. Bioimaging and pulmonary applications of self-assembled Flt1 peptide-hyaluronic acid conjugate nanoparticles. Biomaterials 2013; 34:8478–90.
48. Chen YD, Liang ZY, Cen YY et al. Development of oral dispersible tablets containing prednisolone nanoparticles for the management of pediatric asthma. Drug Des Devel Ther 2015; 9:5815–25.
49. Wang W, Zhu R, Xie Q et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine 2012; 7:3667–77.
50. Yoo D, Guk K, Kim H, Khang G, Wu D, Lee D. Antioxidant polymeric nanoparticles as novel therapeutics for airway inflammatory diseases. Int J Pharm 2013; 450:87–94.
51. Park HS, Kim KH, Jang S et al. Attenuation of allergic airway inflammation and hyperresponsiveness in a murine model of asthma by silver nanoparticles. Int J Nanomedicine 2010; 5:505–15.
52. Halwani R, Shaik SA, Ratemi E et al. Novel anti-IL4Rα nanoparticle efficiently controls lung inflammation during asthma. Exp Mol Med 2016. Manuscript Accepted.
53. Hardy CL, LeMasurier JS, Belz GT et al. Inert 50-nm polystyrene nanoparticles that modify pulmonary dendritic cell function and inhibit allergic airway inflammation. J Immunol 2012; 188:1431–41.
54. Chu DF, Gao J, Wang ZJ. Neutrophil-mediated delivery of therapeutic nanoparticles across blood vessel barrier for treatment of inflammation and infection. ACS Nano 2015; 9:11800–11.
55. Mayadas TN, Cullere X, Lowell CA. The multifaceted functions of neutrophils. Annu Rev Pathol 2014; 9:181–218.
56. Chen DL, Schuster DP. Imaging pulmonary inflammation with positron emission tomography: a biomarker for drug development. Mol Pharm 2006; 3:488–95.
57. Al Faraj A, Shaik AS, Afzal S, Al Sayed B, Halwani R. MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int J Nanomed 2014; 9:1491–503.
58. Shen JY, Chelvam V, Cresswell G, Low PS. Use of folate-conjugated imaging agents to target alternatively activated macrophages in a murine model of asthma. Mol Pharm 2013; 10:1918–27.
59. Mackay PS, Kremers GJ, Kobukai S et al. Multimodal imaging of dendritic cells using a novel hybrid magneto-optical nanoprobe. Nanomedicine 2011; 7:489–96.
60. Markus MA, Napp J, Behnke T et al. Tracking of inhaled near-infrared fluorescent nanoparticles in lungs of SKH-1 mice with allergic airway inflammation. ACS Nano 2015; 9:11642–57.
61. Frohlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int J Nanomedicine 2012; 7:5577–91.
62. Karakoti AS, Hench LL, Seal S. The potential toxicity of nanomaterials - The role of surfaces. JOM 2006; 58:77–82.
63. Kumar V, Kumari A, Guleria P, Yadav SK. Evaluating the toxicity of selected types of nanochemicals. Rev Environ Contam Toxicol 2012; 215:39–121.
64. Tenzer S, Docter D, Rosfa S et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 2011; 5:7155–67.
65. Almeida JP, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine (Lond) 2011; 6:815–35.
66. Hussain S, Vanoirbeek JAJ, Luyts K et al. Lung exposure to nanoparticles modulates an asthmatic response in a mouse model. Eur Respir J 2011; 37:299–309.
67. Glista-Baker EE, Taylor AJ, Sayers BC, Thompson EA, Bonner JC. Nickel nanoparticles cause exaggerated lung and airway remodeling in mice lacking the T-box transcription factor, TBX21 (T-bet). Part Fibre Toxicol 2014; 11:e77730.
68. Shurin MR, Yanamala N, Kisin ER et al. Graphene oxide attenuates Th2-type immune responses, but augments airway remodeling and hyperresponsiveness in a murine model of asthma. ACS Nano 2014; 8:5585–99.
69. Ronzani C, Casset A, Pons F. Exposure to multi-walled carbon nanotubes results in aggravation of airway inflammation and remodeling and in increased production of epithelium-derived innate cytokines in a mouse model of asthma. Arch Toxicol 2014; 88:489–99.
70. Itskovitz-Eldor J, Schuldiner M, Karsenti D et al. Differentiation of human embryonic stem cells into embryoid bodies comprising the three embryonic germ layers. Mol Med 2000; 6:88–95.
71. Kajstura J, Rota M, Hall SR et al. Evidence for human lung stem cells. N Engl J Med 2011; 364:1795–806.
72. Huertas A, Palange P. Circulating endothelial progenitor cells and chronic pulmonary diseases. Eur Respir J 2011; 37:426–31.
73. Rankin S. Mesenchymal stem cells. Thorax 2012; 67:565–6.
74. Al Faraj A, Shaik AS, Shaik AP, Al Sayed B. Enhanced magnetic delivery of superparamagnetic iron oxide nanoparticles to the lung monitored using noninvasive MR. J Nanopart Res 2014; 16:2667.
75. Popescu FD. Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med 2005; 9:840–53.
76. Khaitov MR, Shilovskiy IP, Nikonova AA et al. Small interfering RNAs targeted to interleukin-4 and respiratory syncytial virus reduce airway inflammation in a mouse model of virus-induced asthma exacerbation. Hum Gene Ther 2014; 25:642–50.
77. Zafra MP, Mazzeo C, Gamez C et al. Gene silencing of SOCS3 by siRNA intranasal delivery inhibits asthma phenotype in mice. PLoS One 2014; 9:e91996.
78. Seguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2009; 18:1505–17.
79. Freeley M, Long A. Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection. Biochem J 2013; 455:133–47.
80. Wu W, Chen H, Li YM, Wang SY, Diao X, Liu KG. Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma. Int J Clin Exp Pathol 2014; 7:5505–14.
81. Wu W, Wang T, Dong JJ, Liao ZL, Wen FQ. Silencing of c-kit with small interference RNA attenuates inflammation in a murine model of allergic asthma. Int J Mol Med 2012; 30:63–8.
82. Gavrila A, Chachi L, Tliba O, Brightling C, Amrani Y. Effect of the plant derivative Compound A on the production of corticosteroid-resistant chemokines in airway smooth muscle cells. Am J Respir Cell Mol Biol 2015; 53:728–37.
83. Ohta Y, Hayashi M, Kanemaru T, Abe K, Ito Y, Oike M. Dual modulation of airway smooth muscle contraction by Th2 cytokines via matrix metalloproteinase-1 production. J Immunol 2008; 180:4191–9.
84. Perry MM, Durham AL, Austin PJ, Adcock IM, Chung KF. BET bromodomains regulate transforming growth factor-beta-induced proliferation and cytokine release in asthmatic airway smooth muscle. J Biol Chem 2015; 290:9111–21.
85. Kinyanjui MW, Fixman ED. Cell-penetrating peptides and proteins: new inhibitors of allergic airways disease. Can J Physiol Pharmacol 2008; 86:1–7.
86. Lovinsky-Desir S, Miller RL. Epigenetics, asthma, and allergic diseases: a review of the latest advancements. Curr Allergy Asthma Rep 2012; 12:211–20.
87. Stefanowicz D, Hackett TL, Garmaroudi FS et al. DNA methylation profiles of airway epithelial cells and PBMCs from healthy, atopic and asthmatic children. PLoS One 2012; 7:e44213.
88. Wu CJ, Yang CY, Chen YH, Chen CM, Chen LC, Kuo ML. The DNA methylation inhibitor 5-azacytidine increases regulatory T cells and alleviates airway inflammation in ovalbumin-sensitized mice. Int Arch Allergy Immunol 2013; 160:356–64.
89. Banerjee A, Trivedi CM, Damera G et al. Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models. Am J Respir Cell Mol Biol 2012; 46:132–8.
90. Smarr CB, Yap WT, Neef TP et al. Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization. Proc Natl Acad Sci USA 2016; 113:5059–64.
91. Yarova PL, Stewart AL, Sathish V et al. Calcium-sensing receptor antagonists abrogate airway hyperresponsiveness and inflammation in allergic asthma. Sci Transl Med 2015; 7:284ra60.
92. Xu Q, Ensign LM, Boylan NJ et al. Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo. ACS Nano 2015; 9:9217–27.